Sarepta Therapeutics, Inc. (SRPT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SRPT Revenue Growth
Revenue Breakdown
SRPT's revenue distribution by segment and geography
By Geography
SRPT Revenue Analysis (2014–2025)
As of May 8, 2026, Sarepta Therapeutics, Inc. (SRPT) generated trailing twelve-month (TTM) revenue of $2.18 billion, reflecting slight decline in growth of -1.9% year-over-year. The most recent quarter (Q1 2026) recorded $730.8 million in revenue, up 65.0% sequentially.
Looking at the longer-term picture, SRPT's 5-year compound annual growth rate (CAGR) stands at +32.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $2.20 billion in 2025, representing a new all-time high.
When compared to Healthcare sector peers including BMRN (+9.9% YoY), ALNY (+82.6% YoY), and RARE (+13.3% YoY), SRPT has underperformed the peer group in terms of revenue growth. Compare SRPT vs BMRN →
SRPT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SRPTCurrent | $2.2B | -1.9% | +32.4% | -29.9% | |
 BMRN | $3.2B | +9.9% | +11.6% | 16.6% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% |
SRPT Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.20B | +15.6% | $1.32B | 59.9% | $-657,772,000 | -29.9% |
| 2024 | $1.90B | +53.0% | $1.58B | 83.2% | $218.1M | 11.5% |
| 2023 | $1.24B | +33.3% | $1.09B | 87.9% | $-267,824,000 | -21.5% |
| 2022 | $933.0M | +32.9% | $793.0M | 85.0% | $-536,201,000 | -57.5% |
| 2021 | $701.9M | +30.0% | $604.8M | 86.2% | $-459,710,000 | -65.5% |
| 2020 | $540.1M | +41.8% | $476.7M | 88.3% | $-564,163,000 | -104.5% |
| 2019 | $380.8M | +26.5% | $324.2M | 85.1% | $-705,563,000 | -185.3% |
| 2018 | $301.0M | +94.7% | $266.8M | 88.6% | $-343,628,000 | -114.1% |
| 2017 | $154.6M | +2751.6% | $147.2M | 95.2% | $-171,638,000 | -111.0% |
| 2016 | $5.4M | +332.6% | $5.3M | 97.6% | $-266,730,000 | -4920.3% |
See SRPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SRPT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SRPT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSRPT — Frequently Asked Questions
Quick answers to the most common questions about buying SRPT stock.
Is SRPT's revenue growth accelerating or slowing?
SRPT revenue growth slowed to -1.9%, below the 5-year CAGR of +32.4%. TTM revenue is $2.2B. The deceleration marks a shift from historical growth rates.
What is SRPT's long-term revenue growth rate?
Sarepta Therapeutics, Inc.'s 5-year revenue CAGR of +32.4% reflects the variable expansion pattern. Current YoY growth of -1.9% is near this long-term average.
How is SRPT's revenue distributed by segment?
SRPT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.